Legal & General Pharma Breakthrough UCITS ETF (BIGT)
No change
- Add to watchlist
- Create an alert
- This stock can be held in a
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
REPLICATION
SECURITIES LENDING
COUNTERPARTIES
| Security | Weight |
|---|---|
| CHUGAI PHARMACEUTICAL CO | 17.38% |
| TAKEDA PHARMACEUTICAL CO | 15.64% |
| KYOWA HAKKO KIRIN CO. | 15.26% |
| EISAI CO. | 15.00% |
| JCR PHARMACEUTICAL CO | 14.81% |
| NIPPON SHINYAKU CO | 14.55% |
| SWEDISH ORPHAN BIOVITRUM AB (PUBL) | 1.45% |
| INNOVENT BIOLOGICS INC | 1.27% |
| SINO BIOPHAMACEUTICAL | 0.98% |
| INNOCARE PHARMA LTD | 0.88% |
ASSET SPLIT
Annual & interim reports
Before you invest, please make sure you read the documents below
OBJECTIVE
| Index: | [No Data] |
|---|---|
| Aim: |
[No Data]
Read full aim for Legal & General |
| Leverage: | 100% |
| Currency hedging: | n/a |
COSTS
| Ongoing Charge (OCF/TER): | 0.49% |
|---|---|
| Management fee: | 0.75% |
| Indicative spread: | 0.52% |
In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.
Company announcements
No company announcements about Legal & General Pharma Breakthrough UCITS ETF were found.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.